Year in review: The standout health stories of 2025, from measles outbreaks to AI-made viruses

Live Science's year‑end roundup catalogs a string of public‑health and biotech risks that could influence policy and sector flows: a sustained measles resurgence threatening U.S. elimination status; politicization of mRNA research and major USAID funding cuts that imperil global HIV/TB programs and R&D; and the emergence of AI tools capable of designing viruses, raising biosecurity and regulatory scrutiny. Collectively these developments increase regulatory and geopolitical risk for biotech and public‑health funding, suggesting potential repricing for firms reliant on vaccine/R&D continuity and possible shifts toward government spending on biosecurity and pandemic preparedness.

Analysis

Market structure: Incumbent vaccine and diagnostics franchises (e.g., MRK, PFE, TMO) are positioned to capture near-term demand from measles resurgence and biodefense stockpiling, increasing pricing power for finished vaccines and lab consumables by an estimated 5–15% revenue tail over 12–24 months. Small-cap mRNA and clinical-stage biotech (XBI constituents, pure-play MRNA) face revenue and financing compression if U.S. politicization and USAID funding cuts persist, shifting share toward vertically integrated incumbents and specialty suppliers.

Risk assessment: Tail risks include a dual-use AI-designed pathogen event or major regulatory clampdowns on fetal-tissue/mRNA research that could trigger >30% re-rating across small biotech within days; conversely, a bipartisan biodefense spending surge would re-rate suppliers positively. Immediate (days–weeks) equity volatility will be driven by headlines; medium term (3–12 months) by regulatory actions and budget cycles; structural effects play out over 1–3 years as funding and supply chains adjust.

Trade implications: Favor large-cap vaccine/diagnostic longs and lab-supply longs while hedging mRNA policy risk via options; expect 6–18 month asymmetry where MRK/PFE/TMO outperform XBI/MRNA by 10–25% under base case. Use pair trades to exploit divergent funding sensitivity and buy implied-volatility protection around near-term policy announcements.

Contrarian angles: Consensus underestimates how regulation can entrench incumbents—stricter U.S. research limits would reduce competition and increase pricing for legacy vaccines, benefiting MRK/PFE. The panic premium on “AI-designed virus” headlines may overshoot; selectively buy deep-value small-cap tools names after 20–40% headline-driven selloffs rather than chasing momentum.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Merck (MRK) with a 12–18 month horizon; target +20–30% upside if vaccine demand/stockpiling increases, use a 12% hard stop-loss or trim if downside risk materializes.
• Allocate 1–1.5% long to Thermo Fisher (TMO) and/or IQVIA (IQV) as defensive exposure to lab-supply and contract services; hold 9–18 months and rotate profits into higher-volatility biotech on >25% pullbacks.
• Hedge mRNA/regulatory risk: buy 9–12 month MRNA put options equal to 1% portfolio notional (e.g., 25–35% OTM puts) or construct a put spread to cap cost; trigger to increase hedge to 2% if major federal regulatory action is announced.
• Pair trade: long PFE (2%) and short XBI ETF (1%) for 6–12 months to capture rotation from small clinical biotechs to large, cash-generative vaccine makers; rebalance if relative performance gap narrows to <5%.